Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EBITDA (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed EBITDA for 6 consecutive years, with $17.1 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 150.98% to $17.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$10.5 million through Dec 2025, up 82.72% year-over-year, with the annual reading at -$10.5 million for FY2025, 82.72% up from the prior year.
  • EBITDA hit $17.1 million in Q4 2025 for Insight Molecular Diagnostics, up from -$11.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $17.1 million in Q4 2025 to a low of -$35.7 million in Q4 2021.
  • Historically, EBITDA has averaged -$9.4 million across 5 years, with a median of -$9.6 million in 2024.
  • Biggest five-year swings in EBITDA: plummeted 469.33% in 2021 and later soared 293.9% in 2023.
  • Year by year, EBITDA stood at -$35.7 million in 2021, then surged by 67.35% to -$11.6 million in 2022, then crashed by 38.9% to -$16.2 million in 2023, then plummeted by 107.84% to -$33.6 million in 2024, then soared by 150.98% to $17.1 million in 2025.
  • Business Quant data shows EBITDA for IMDX at $17.1 million in Q4 2025, -$11.0 million in Q3 2025, and -$9.8 million in Q2 2025.